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Alternative splicing of fibronectin pre-mRNA at the 
ED-A region has been shown to be regulated in a tissue- 
and developmental stage-specific manner. We investi- 
gated the splicing pattern at this region in malignant 
and nonmalignant human liver  tissues and found that 
the relative population of the fibronectin mRNA con- 
taining the ED-A sequence is markedly increased in 
malignant liver tumors.  Nontumorous liver tissues in- 
cluding those with chronic hepatitis and cirrhosis did 
not show any significant change in the alternative 
splicing  at the ED-A region. It was also found that the 
increased expression of the ED-A-containing fibronec- 
tin mRNA closely correlates with the occurrence of 
portal vein tumor  thrombus and intrahepatic metasta- 
sis, which  are  two characteristic features of invasive 
liver tumors. These results indicate that tissue-specific 
alternative  splicing of fibronectin mRNA is modified 
in human liver cancer and raise a possibility that the 
putative molecular machinery governing alternative 
RNA splicing of not only fibronectin but also other 
cellular proteins is deregulated in malignant human 
tumors. 
Fibronectin (FN),’ a high molecular weight glycoprotein 
present  in  the  extracellular  matrix  and  various body fluids, 
plays an important role in many aspects of cell-substrate 
interactions including cell adhesion, migration, differentia- 
tion,  and  malignant  transformation (1-5). FN is  made  up of 
three  types of internally homologous repeats  referred to  as 
type  I,  type 11, and  type I11 (6), each encoded  by  a  single, or 
at  most a pair of exon(s) (4, 7, 8). Recent studies on the 
cloning and sequencing of the FN gene and cDNAs have 
revealed that  up  to 20 different FN isoforms can  be  generated 
from a single gene by alternative  pre-mRNA splicing at three 
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distinct regions termed ED-A, ED-B, and IIICS (8-12). Al- 
ternative splicing a t  these regions appears  to be regulated in 
a tissue-  or cell type-specific manner; for  example,  more ED- 
A+ mRNAs  than  ED-A-  mRNA  are expressed  in the  lung  and 
cultured  lung  fibroblasts  whereas  the liver  expresses almost 
exclusively the  ED-A-  mRNA (13-15). Tissue-  or cell type- 
specific expression of the  ED-A region has  been also demon- 
strated  at  the  protein level using  site-specific antibodies (16- 
20). 
Recently, we have found  that  human  fetal liver  expresses  a 
significant  amount of the  ED-A+  mRNA,  as  contrasted  to  the 
almost exclusive expression of the ED-A- mRNA  in  the  adult 
liver  (15). These  results suggest that  the  alternative splicing 
of FN  pre-mRNA  is developmentally  regulated in  the liver. 
Since many fetal antigens and isozymes are expressed in 
malignant  tumors,  these  results raised  a  possibility that  the 
ED-A+  mRNA is retrodifferentially expressed in liver cancer. 
In  this  report, we present evidence that  the  ED-A+  mRNA is 
indeed  expressed  in human liver cancer  and  that  the  increase 
of the  ED-A+  mRNA is closely associated with the invasive- 
ness of the  tumor. 
MATERIALS AND METHODS 
Tissues-Human hepatocellular carcinoma (HCC) tissues as well 
as the surrounding nontumorous tissues were obtained from the 
surgically resected specimens for pathological examination. The mac- 
roscopic grading of HCCs was determined as described by Kanai et 
al. (21). The tissue specimens were immediately frozen at -85 “C 
after surgical resection. Tissue specimens with chronic hepatitis and 
cirrhosis were obtained from the nontumorous area distal from the 
tumor loci. The numbers of specimens examined for each tissue type 
were as follows; normal adult lung, 3; normal adult liver, 4; fetal liver, 
5; liver with chronic hepatitis, 6; liver cirrhosis, 10; hepatocellular 
adenoma, 1; type I HCC, 7; type I1 HCC, 10; HCC transplanted in 
nude mouse, 2. 
Nuclease S1 Protection Analysis-Total RNA was prepared from 
0.5-2.0 g of frozen tissues as described previously (22). Nuclease S1 
protection analysis was performed as described by Berk and  Sharp 
(23) .  The probe DNA for the ED-A region  was prepared from the  FN 
cDNA clone pFH111, which was kindly provided by Drs. A. R. 
Kornblihtt and F. E. Baralle, as described previously (15). The 3’ 
end-labeled single-stranded probe DNA  was hybridized with 5-10  pg 
of RNAs extracted from various liver tissues in 30  pl  of  40 mM PIPES 
buffer, pH 6.4, containing 1 mM EDTA, 0.4 M NaC1, and 80% 
formamide at 53 “C for 18 h. The DNA/RNA hybrids were digested 
with 800 units of nuclease S1 (Boehringer Mannheim Yamanouchi, 
Tokyo, Japan)  at 37 “C for 30 min as described (15). The nuclease- 
resistant  fragments were analyzed on 6% polyacrylamide sequencing 
gels containing 7 M urea and subsequent autoradiography. The rela- 
tive radioactivities of the nuclease-resistant fragments were deter- 
mined with a Fujix Bio-Image Analyzer BAlOO (Fuji Photo Film Co., 
Ltd., Kanagawa, Japan) using phosphor imaging plates  (24). 
RESULTS AND DISCUSSION 
Alternative splicing of FN  pre-mRNA at the ED-A  region 
was analyzed by nuclease S1 protection  analysis using as a 
probe the  antisense  strand  cDNA covering the  entire  ED-A 
sequence (Fig. 1). The  probe  DNA  is designed to yield, upon 
nuclease S1 digestion, either a 481- or 105-base fragment 
(referred  to  as  “ED-A+”  and “ED-A”’ fragment, respectively) 
when  protected by the  FN  mRNA species containing  or lack- 
ing  the  ED-A sequence  (Fig. lA). Hybridization of the probe 
DNA with total RNA extracted from the adult liver gave 
almost exclusively the ED-A- fragment which was actually 
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FIG. 1. Patterns of the alternative 
splicing of FN pre-mRNA at the ED- 
A region  studied by nuclease S 1 pro- 
tection analysis. A ,  schematic repre- 
sentation of the probe DNA  and  its  pu- 
tative  fragments  protected by FN mRNA 
species containing  or  lacking  the  ED-A 
sequence. The probe DNA contains an 
extra nucleotide derived from a cloning 
vector at   the 5' end  (shown by wavy line), 
which serves as a control substrate for 
monitoring nuclease activity. The open 
box represents the ED-A sequence. B,  
autoradiogram of the  nuclease-resistant 
fragments of the  probe DNA protected 
by hybridization with RNAs extracted 
from rat  pituitary (lane 2 )  and  the fol- 
lowing human  tissues except lane Z (the 
probe DNA without nuclease digestion); 
lane 3, normal  adult lung; lane 4 ,  normal 
adult liver; lane 5, normal  fetal liver; lane 
6, liver with chronic hepatitis; lane 7, 
liver with cirrhosis; lane 8, benign hepa- 
tocellular  adenoma; lane 9, HCC  without 
extranodular  tumor growth (type I 
HCC); lane 10, HCC  with  extranodular 
tumor growth (type I1 HCC); lane Zl, 
transplanted  HCC grown in a nude 
mouse. The positions of the expected 
fragments  protected by the  ED-A+  and 
ED-A- FN mRNA species (right) and 
the molecular  weight markers  (the Tag1 
digest of 6x174 DNA, left) are  indicated 
in the margin. C, relative  abundance of 
the  ED-A+  mRNA species in  noncancer- 
ous and cancerous human liver tissues. 
Relative  radioactivities of the  ED-A+ 
and ED-A- fragments were determined 
by a Fujix Bio-Image Analyzer BAlOO 
and expressed as a percentage of the 
total  radioactivities recovered in both 
fragments. The results  are  xpressed 
with  mean  standard  deviation. 
A 






resolved into  three  bands differing in size by one  or  two  bases 
(Fig. lB, lane 4; see also Fig. IC). Heterogeneity of this 
fragment  is  probably  due  to  the exc ssive attack of the  termini 
of the  DNA/RNA  hybrid by the nuclease. In  contrast,  more 
ED-A+ than ED-A- fragment was  produced upon  protection 
with the RNA extracted from adult lung (Fig. lB, lane 3), 
confirming  tissue specificity in  alternative  pre-mRNA  splicing 
at   the ED-A region (15). None of these  fragments  was gen- 
erated when the  probe  DNA was hybridized with  rat  RNA 
(Fig. lB, lane 2).  Unlike  the  adult liver, a significant  amount 
of the  ED-A+  mRNA was expressed  in  the  fetal liver (Fig. lB, 
lane 5; also see Fig. IC), being  consistent  with  our previous 
observations (15). 
In order to see whether alternative splicing of FN pre- 
mRNA  is modified in  various liver  diseases, we examined  the 
splicing pattern  at  the  ED-A region in both nonmalignant 
and  malignant liver  tissues. Hybridization of the  probe  DNA 
with  RNAs  extracted  from  human liver tissues  with  chronic 
hepatitis,  cirrhosis,  and  benign  hepatocellular  adenoma 
yielded predominantly  the ED-A- fragment (Fig. lB, lanes 6- 
8; see also Fig. IC), indicating that tissue-specific pre-mRNA 
splicing at   the ED-A region is  not affected in  these  nonmalig- 
nant liver  diseases. 
However, a significant  increase of the  ED-A+  mRNA was 
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estingly, the  HCC  without  extranodular  tumor growth,  mac- 
roscopically classified as type I (21), exhibited  only a marginal 
increase, if any, in the ED-A+ mRNA (Fig. lB, lane 9 ) ,  
although  the  HCC showing extranodular  tumor growth,  mac- 
roscopically classified as  type 11, was  found  to  express a large 
amount of the  ED-A+  mRNA (Fig. lB, lune IO). Quantitation 
of the relative  radioactivities of the ED-A+ and ED-A-  frag- 
ments generated by protection with RNAs from 17 HCC 
tissues  indicated  that  the ED-A+ mRNA comprises, on  the 
average, 9.6 and 30.4% of the  total  FN  mRNA  in  type I and 
type I1 HCCs, respectively (Fig. IC). Thus,  the  increase  in 
the  ED-A+  mRNA species appears  to be  associated with  the 
malignancy of the tumor. Furthermore, the relative abun- 
dance of the ED-A+ mRNA  is increased  slightly, but signifi- 
cantly, even in type I HCCs when compared with those of 
nonmalignant liver tissues except benign adenoma (0.02 t 
< 0.1). 
In  support of this  notion,  the  increase of the  ED-A+ mRNA 
correlates  with  the  occurrence of portal vein tumor  thrombus 
and  intrahepatic  metastasis,  characteristic  features of HCCs 
with higher  grades of malignancy (Fig. 2). HCCs with portal 
vein tumor  thrombus  expressed  three  to f ur times more ED- 
A+ mRNA than those without it. A similar, but less pro- 
nounced, difference in  the expression of the ED-A+  mRNA 
was  observed  between the  HCCs  with  and  without  intrahe- 
patic  metastasis. 
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FIG. 2. Expression of the ED-A+ mRNA in noninvasive and 
invasive  hepatocellular carcinomas. Relative abundance of the 
ED-A+ mRNA species was determined from the relative radioactivity 
of the ED-A+ and ED-A-  nuclease-resistant  fragments  as described 
in  the legend for Fig. 1C. The t values are  indicated above the burs. 
Histological examination  indicates  that  the increased 
expression of the ED-A’ mRNA  in  malignant HCCs is not 
due to  the  outgrowth of fibroblasts or infiltration of macro- 
phages but  rather  to  the deregulation of the  alternative splic- 
ing of FN  pre-mRNA. Although elaboration of the “feeding 
artery” by the  tumors may also contribute  to  the increase of 
the ED-A’ mRNA,  it is unlikely to be the major  cause  since 
the relative  mass of the  endothelial cells in  the  tumor tissues 
was far less than  that of the  tumor cells. Furthermore,  sinus- 
oidal vessels have  been  known to decrease in  the  tumors. 
Further  support for the deregulated alternative splicing of 
FN  pre-mRNA  at  the  ED-A region was obtained  with  HCC 
tumors grown in nude mice. The  tumors were found to express 
a high level of the  ED-A+  mRNA (Fig. lB, lane 11; also see 
Fig. IC).  Since  the  transplanted  tumors should be free  from 
human  fibroblasts, macrophages, or endothelial cells, the  in- 
crease of the ED-A’ mRNA  must be due to  the deregulation 
of the  alternative mRNA  splicing per se. Mouse  macrophages 
and  endothelial cells infiltrating  the  tumors hould not affect 
the determination of the relative abundance of the ED-A’ 
mRNA, since the probe DNA used can only  be protected by 
human N  mRNA. It should  be noted, however, that we 
cannot eF xclude a  possibility that  the observed changes of the 
ED-A+  mRNA level could be due to  the  differential  turnover 
of the  ED-A+  and ED-A- mRNAs between normal  and malig- 
nant liver tissues,  since  only the  steady-state levels of these 
two  mRNA species can be determined by  nuclease protection 
analysis.  There  has been reported, however, no evidence that 
these two FN mRNA species differ in  the  stability  in  cultured 
cells or tissues. 
Physiological significance of the increased  expression of the 
ED-A  containing FN isoforms has  not  yet been well under- 
stood  but may well be involved in the  manifestation of the 
invasive properties of the  malignant  tumor cells. It should  be 
noted, however, that  the increased  expression of the  ED-A- 
containing isoforms per se is not sufficient  for the  HCC cells 
to acquire  invasive properties, because normal  lung  and  en- 
dometrial  tissues  are shown to express  a  large amount of the 
ED-A-containing isoforms (15). 
Tumor progression is considered to be a multistep process 
requiring not only altered cell-cell and  cell-substrate adhesion 
but also alterations  in cytoskeltal organization, signal trans- 
duction, and secretion of degradative enzymes (25, 26). A 
possible scenario would be, therefore, that the molecular 
machinery governing alternative pre-mRNA splicing is de- 
regulated  in malignant  HCC cells, triggering  pleiotropic alter- 
ation of the isoform diversity of not only FN  but also many 
other  proteins whose RNA transcripts  are  alternatively proc- 
essed. An increasing number of genes, including those of 
cytoskeltal components such as tropomyosin (27, 28), tro- 
ponin (29), myosin light chain (30,  31), and vinculin (32),  as 
well as  that of protein  kinase C  (33),  have now been  shown 
to be processed by alternative RNA splicing. 
Transformation-associated  changes of the  alternative splic- 
ing at  the  ED-A region have  been reported for virally trans- 
formed cultured cells at  both  the  protein  and  mRNA levels 
(8, 14, 18). Similarly, the isoform diversity of tropomyosin 
was shown to be significantly altered in  virally transformed 
fibroblasts (34, 35).  Despite these in vitro observations,  it  has 
not been clear whether  the  alternative  pre-mRNA splicing of 
these proteins is also altered in naturally occurring human 
cancer. Our results provide, as  far  as we know, the  first  direct 
evidence for the  aberrant regulation of the  alternative  RNA 
splicing in human cancer. Further studies on the tissue- 
specific and oncodevelopmental  regulation of differential 
RNA  processing  should  provide an  insight for better  under- 
standing  the molecular basis of tumor progression. 
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